The North America Pigmentation Disorder Treatment Market would witness market growth of 4.2% CAGR during the forecast period (2023-2030).
The main factor promoting the development of the market is the rise in the number of people suffering from pigmentation disorders. Numerous nations have a large number of pigmentation disorder patients who need the development of effective pigmentation disorder treatments. In addition, rising demand for cutting-edge treatments for pigmentation disorders and increased government spending on the pharmaceutical and biotechnology industries in developing countries are predicted to positively impact the market. Furthermore, the market is anticipated to grow during the forecast period due to boosted awareness about pigmentation disorders.
Increasing emphasis on developing safe and effective pigmentation disorder treatments is one of the main trends in the market. Due to the prevalence of pigmentation disorders and the rise in demand for novel treatments, market participants emphasize developing and launching safe and effective treatments. This is anticipated to persist throughout the forecast period, driving market expansion.
North America experiences significant sun exposure, especially in regions with high ultraviolet (UV) radiation levels. Prolonged and unprotected sun exposure can cause various pigmentation disorders, including solar lentigines and melasma. The aging population in North America is growing, and many pigmentation disorders are more common with age. Age-related skin changes, such as solar lentigines and actinic keratosis, contribute to the prevalence of pigmentation disorders. North America is ethnically diverse, and individuals with skin of colour are susceptible to specific pigmentation disorders, such as melasma, post-inflammatory hyperpigmentation (PIH), and vitiligo. These conditions can affect a significant portion of the population. Thus, the increase in the prevalence of pigmentation disorder conditions in North America has been a notable trend in recent years, which is beneficial for the growth of the market.
The US market dominated the North America Pigmentation Disorder Treatment Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $315.2 million by 2030. The Canada market is experiencing a CAGR of 6.5% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.6% during (2023 - 2030).
Based on Type, the market is segmented into Vitiligo, Melasma, and Others. Based on Treatment, the market is segmented into Corticosteroids, Calcineurin Inhibitor, and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, & Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Bausch Health Companies Inc, Glenmark Pharmaceuticals Limited, Obagi Cosmeceuticals LLC, AbbVie, Inc., Dermavant Sciences, Inc. (Roivant Sciences Ltd.), Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Galderma S.A., Viatris, Inc. (Mylan N.V.), and Pfizer, Inc.
The main factor promoting the development of the market is the rise in the number of people suffering from pigmentation disorders. Numerous nations have a large number of pigmentation disorder patients who need the development of effective pigmentation disorder treatments. In addition, rising demand for cutting-edge treatments for pigmentation disorders and increased government spending on the pharmaceutical and biotechnology industries in developing countries are predicted to positively impact the market. Furthermore, the market is anticipated to grow during the forecast period due to boosted awareness about pigmentation disorders.
Increasing emphasis on developing safe and effective pigmentation disorder treatments is one of the main trends in the market. Due to the prevalence of pigmentation disorders and the rise in demand for novel treatments, market participants emphasize developing and launching safe and effective treatments. This is anticipated to persist throughout the forecast period, driving market expansion.
North America experiences significant sun exposure, especially in regions with high ultraviolet (UV) radiation levels. Prolonged and unprotected sun exposure can cause various pigmentation disorders, including solar lentigines and melasma. The aging population in North America is growing, and many pigmentation disorders are more common with age. Age-related skin changes, such as solar lentigines and actinic keratosis, contribute to the prevalence of pigmentation disorders. North America is ethnically diverse, and individuals with skin of colour are susceptible to specific pigmentation disorders, such as melasma, post-inflammatory hyperpigmentation (PIH), and vitiligo. These conditions can affect a significant portion of the population. Thus, the increase in the prevalence of pigmentation disorder conditions in North America has been a notable trend in recent years, which is beneficial for the growth of the market.
The US market dominated the North America Pigmentation Disorder Treatment Market, By Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $315.2 million by 2030. The Canada market is experiencing a CAGR of 6.5% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.6% during (2023 - 2030).
Based on Type, the market is segmented into Vitiligo, Melasma, and Others. Based on Treatment, the market is segmented into Corticosteroids, Calcineurin Inhibitor, and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies, & Online Pharmacies. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Bausch Health Companies Inc, Glenmark Pharmaceuticals Limited, Obagi Cosmeceuticals LLC, AbbVie, Inc., Dermavant Sciences, Inc. (Roivant Sciences Ltd.), Incyte Corporation, Dr. Reddy’s Laboratories Ltd., Galderma S.A., Viatris, Inc. (Mylan N.V.), and Pfizer, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type- Vitiligo
- Melasma
- Others
- Corticosteroids
- Calcineurin Inhibitor
- Others
- Drug Store & Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Bausch Health Companies Inc
- Glenmark Pharmaceuticals Limited
- Obagi Cosmeceuticals LLC
- AbbVie, Inc.
- Dermavant Sciences, Inc. (Roivant Sciences Ltd.)
- Incyte Corporation
- Dr.Reddy’s Laboratories Ltd.
- Galderma S.A.
- Viatris, Inc. (Mylan N.V.)
- Pfizer, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. North America Pigmentation Disorder Treatment Market, By Type
Chapter 5. North America Pigmentation Disorder Treatment Market, By Treatment
Chapter 6. North America Pigmentation Disorder Treatment Market, By Distribution Channel
Chapter 7. North America Pigmentation Disorder Treatment Market, By Country
Chapter 8. Company Profiles
Companies Mentioned
- Bausch Health Companies Inc
- Glenmark Pharmaceuticals Limited
- Obagi Cosmeceuticals LLC
- AbbVie, Inc.
- Dermavant Sciences, Inc. (Roivant Sciences Ltd.)
- Incyte Corporation
- Dr. Reddy’s Laboratories Ltd.
- Galderma S.A.
- Viatris, Inc. (Mylan N.V.)
- Pfizer, Inc.
Methodology
LOADING...
